Double-blind, randomized, placebo-controlled pilot study of the phosphodiesterase-3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder.

Mahmoud S AbdallahAhmed N RamadanHend Omara-RedaNoha O MansourMohamed A ElsokaryHozaifa K ElsawahShimaa Abdelsattar ZakiHend E Abo MansourEsraa M Mosalam

Published in: CNS neuroscience & therapeutics (2021)

CLS is safe and effective short-term adjunctive therapy in patients with MDD with no other comorbid conditions. Trial registration ID:NCT04069819.

Keyphrases

major depressive disorder
placebo controlled
double blind
phase iii
phase ii
study protocol
clinical trial
bipolar disorder
phase ii study
open label
randomized controlled trial
mesenchymal stem cells
stem cells
cell therapy
bone marrow
radiation therapy